Results 51 to 60 of about 35,241 (222)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

Targeted oncology, 2022
First-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line systemic therapy. Fibroblast growth factor receptor (FGFR)-2 fusions/rearrangements can be oncogenic drivers, occurring
G. Abou-Alfa, K. Bibeau, N. Schultz, Amin Yaqubie, Brittanie M Millang, H. Ren, L. Féliz   +6 more
semanticscholar   +1 more source

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy

Clinical Cancer Research
Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers
Alberto Gonzalez-Medina, Maria Vila-Casadesús, Marina Gómez-Rey, C. Fabregat-Franco, Alexandre Sierra, Tian V. Tian, F. Castet, Gloria Castillo, J. Matito, P. Martinez, J. Miquel, P. Nuciforo, R. Pérez-López, T. Macarulla, A. Vivancos   +14 more
semanticscholar   +1 more source

Influence of FGF4 and BMP4 on FGFR2 dynamics during the segregation of epiblast and primitive endoderm cells in the pre-implantation mouse embryo.

PLoS ONE, 2023
Specification of the epiblast (EPI) and primitive endoderm (PE) in the mouse embryo involves fibroblast growth factor (FGF) signaling through the RAS/MAP kinase pathway.
Marcelo D Goissis, Brian Bradshaw, Eszter Posfai, Janet Rossant   +3 more
doaj   +1 more source

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies

Clinical Cancer Research
Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies.
F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur, R. Bahleda, L. Bigot, Rémy Barbé, Catline Nobre, D. Combarel, S. Michiels, A. Italiano, C. Smolenschi, L. Tselikas, J. Scoazec, Santiago Ponce-Aix, Benjamin Besse, F. André, K. Olaussen, A. Hollebecque, L. Friboulet   +19 more
semanticscholar   +1 more source

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Future Oncology, 2020
FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA.
T. Bekaii-Saab, J. Valle, E. Cutsem, L. Rimassa, J. Furuse, T. Ioka, D. Melisi, T. Macarulla, J. Bridgewater, H. Wasan, M. Borad, G. Abou-Alfa, P. Jiang, C. Lihou, H. Zhen, E. Asatiani, L. Féliz, A. Vogel   +17 more
semanticscholar   +1 more source

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Cancer Medicine, 2022
This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements.
G. Shi, Xiao-yong Huang, T. Wen, T. Song, M. Kuang, H. Mou, Lequn Bao, Haifeng Zhao, Hong Zhao, Xielin Feng, Bi-xiang Zhang, T. Peng, Yu-Bao Zhang, Xia Li, Hong-sheng Yu, Yu Cao, Lian-Xin Liu, Ti Zhang, Weilin Wang, Jianghua Ran, Ying-Bin Liu, W. Gong, Mingxia Chen, Lian Cao, Yang Luo, Yan V. Wang, Hui Zhou, Guo-huan Yang, Jia Fan, Jian Zhou   +29 more
semanticscholar   +1 more source

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies

Case Reports in Oncology, 2020
Cholangiocarcinoma is a very heterogenous cancer and “target-rich” disease. While the current classifications are based on the anatomic location of these tumors (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer ...
Pashtoon Murtaza Kasi
doaj   +1 more source

A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers

Frontiers in Oncology, 2021
Background: Fibroblast growth factor receptor 2 (FGFR2) is frequently altered in tumors and one of the top therapeutic targets in cholangiocarcinoma (CHOL) with FGFR2 fusions. Although there have been several studies on individual tumors, a comprehensive
Juanni Li, Kuan Hu, Jinzhou Huang, Lei Zhou, Yuanliang Yan, Yuanliang Yan, Zhijie Xu   +6 more
doaj   +1 more source

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Biomedicines
Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst ...
David K. Lau, Jack P. Collin, J. Mariadason   +2 more
semanticscholar   +1 more source

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.

The Journal of the National Comprehensive Cancer Network, 2022
Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of diagnosis.
Camille Ng, J. Glaspy, Veronica R. Placencio-Hickok, Shant Thomassian, J. Gong, A. Osipov, A. Hendifar, Natalie Moshayedi   +7 more
semanticscholar   +1 more source